The role of CD200 in immunity to B cell lymphoma

Journal of Leukocyte Biology

Suchinta Shaha²  David E. Spaner¹  Karrie K. Wong³  Reginald M. Gorczynski³  Ismat Khatri⁴ 

[1] Division of Molecular and Cellular Biology, Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada Division of Molecular and Cellular Biology, Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Division of Molecular and Cellular Biology, Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada Division of Molecular and Cellular Biology, Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada;Division of Molecular and Cellular Biology, Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Division of Molecular and Cellular Biology, Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Division of Molecular and Cellular Biology, Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; andInstitute of Medical Science and Transplant Research Division, University Health Network, University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science and Institute of Medical Science and Transplant Research Division, University Health Network, University of Toronto, Toronto, Ontario, Canada; Transplant Research Division, University Health Network, University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science and Transplant Research Division, University Health Network, University of Toronto, Toronto, Ontario, Canada;Transplant Research Division, University Health Network, University of Toronto, Toronto, Ontario, Canada; Transplant Research Division, University Health Network, University of Toronto, Toronto, Ontario, Canada; Transplant Research Division, University Health Network, University of Toronto, Toronto, Ontario, Canada;

关键词: cancer;    immune evasion;    cancer immunology;   

DOI  :  10.1189/jlb.1009686

学科分类：生理学

来源: Federation of American Societies for Experimental Biology

【 摘 要 】

CD200 is a transmembrane protein broadly expressed on a variety of cell types, which delivers immunoregulatory signals through binding to receptors (CD200Rs) expressed on monocytes/myeloid cells and T lymphocytes. Signals delivered through the CD200:CD200R axis have been shown to play an important role in the regulation of anti-tumor immunity, and overexpression of CD200 has been reported in a number of malignancies, including CLL, as well as on cancer stem cells. We investigated the effect of CD200 blockade in vitro on a generation of CTL responses against a poorly immunogenic CD200+ lymphoma cell line and fresh cells obtained from CLL patients using anti-CD200 mAb and CD200-specific siRNAs. Suppression of functional expression of CD200 augmented killing of the CD200+ cells, as well as production of the inflammatory cytokines IFN-γ and TNF-α by effector PBMCs. Killing was mediated by CD8+ cytotoxic T cells, and CD4+ T cells play an important role in CD200-mediated suppression of CTL responses. Our data suggest that CD200 blockade may represent a novel approach to clinical treatment of CLL.

【 授权许可】

Unknown